AstraZeneca, MSD sue MSN and Sandoz over Calquence generics

AstraZeneca and Merck, Sharp & Dohme (MSD) have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence (acalabrutinib) infringe six patents.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

MSD wins patent extension feud over post-surgery drug

15 June 2023 The three-year dispute revolved around proposed generic versions of a drug used to offset the effects of muscle relaxants | Pharma giant can retain patent until January 2026.

Big Pharma

MSD prevails in diabetes drug dispute with Mylan

29 September 2022 MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.

Generics

MSD targets Mankind’s diabetes generic in patent suit

5 April 2022 Merck Sharp & Dohme has filed a complaint against New Dehli-based Mankind Pharma, looking to halt the approval of a generic version of the type two diabetes treatment, Januvia.

More on this story

Americas

MSD wins patent extension feud over post-surgery drug

15 June 2023 The three-year dispute revolved around proposed generic versions of a drug used to offset the effects of muscle relaxants | Pharma giant can retain patent until January 2026.

Big Pharma

MSD prevails in diabetes drug dispute with Mylan

29 September 2022 MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.

Generics

MSD targets Mankind’s diabetes generic in patent suit

5 April 2022 Merck Sharp & Dohme has filed a complaint against New Dehli-based Mankind Pharma, looking to halt the approval of a generic version of the type two diabetes treatment, Januvia.

More on this story

Americas

MSD wins patent extension feud over post-surgery drug

15 June 2023 The three-year dispute revolved around proposed generic versions of a drug used to offset the effects of muscle relaxants | Pharma giant can retain patent until January 2026.

Big Pharma

MSD prevails in diabetes drug dispute with Mylan

29 September 2022 MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.

Generics

MSD targets Mankind’s diabetes generic in patent suit

5 April 2022 Merck Sharp & Dohme has filed a complaint against New Dehli-based Mankind Pharma, looking to halt the approval of a generic version of the type two diabetes treatment, Januvia.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB

AstraZeneca, MSD sue MSN and Sandoz over Calquence generics

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features